7-氨甲基-螺环[3.5]壬烷 | 877125-98-9

• 物质功能分类: 有机原料 - 氨基化合物
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 7-氨甲基-螺环[3.5]壬烷
• 中文别名: 7-氨基甲基螺[3.5]壬烷
• 英文名称: C-spiro[3.5]non-7-yl-methylamine
• 英文别名: Spiro[3.5]nonan-7-ylmethanamine
• CAS: 877125-98-9
• 化学式: C₁₀H₁₉N
• mdl: MFCD11501147
• 分子量: 153.268
• InChiKey: OPYDFKJFDKKDIO-UHFFFAOYSA-N

物化性质

• 沸点：
  212.9±8.0 °C(Predicted)
• 密度：
  0.95±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2921300090

反应信息

• 作为反应物：
  描述：

  7-氨甲基-螺环[3.5]壬烷 、 4,6-dichloro-2-methylsulfanyl-pyrimidine-5-carboxylic acid methylamide 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 生成 4-chloro-N-methyl-2-(methylthio)-6-((spiro[3.5]nonan-7-ylmethyl)amino)pyrimidine-5-carboxamide
  参考文献：
  名称：

  Overcoming hERG issues for brain-penetrating cathepsin S inhibitors: 2-Cyanopyrimidines. Part 2

  摘要：

  We describe here orally active and brain-penetrant cathepsin S selective inhibitors, which are virtually devoid of hERG K(+) channel affinity, yet exhibit nanomolar potency against cathepsin S and over 100-fold selectivity to cathepsin L. The new non-peptidic inhibitors are based on a 2-cyanopyrimidine scaffold bearing a spiro[3.5] non-6-yl-methyl amine at the 4-position. The brain-penetrating cathepsin S inhibitors demonstrate potential clinical utility for the treatment of multiple sclerosis and neuropathic pain. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.08.067
• 作为产物：
  描述：

  7-azidomethyl-spiro[3.5]nonane 在 三苯基膦 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 23.0h， 生成 7-氨甲基-螺环[3.5]壬烷
  参考文献：
  名称：

  Overcoming hERG issues for brain-penetrating cathepsin S inhibitors: 2-Cyanopyrimidines. Part 2

  摘要：

  We describe here orally active and brain-penetrant cathepsin S selective inhibitors, which are virtually devoid of hERG K(+) channel affinity, yet exhibit nanomolar potency against cathepsin S and over 100-fold selectivity to cathepsin L. The new non-peptidic inhibitors are based on a 2-cyanopyrimidine scaffold bearing a spiro[3.5] non-6-yl-methyl amine at the 4-position. The brain-penetrating cathepsin S inhibitors demonstrate potential clinical utility for the treatment of multiple sclerosis and neuropathic pain. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.08.067

文献信息

• [EN] PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS<br/>[FR] DÉRIVÉS PYRROLIDINE ET LEUR UTILISATION EN TANT QUE MODULATEURS DE LA VOIE DU COMPLÉMENT
  申请人：NOVARTIS AG

  公开号：WO2014002054A1

  公开（公告）日：2014-01-03

  The present invention provides a compound of formula (I) a method for manufacturing the compounds of the invention, and its therapeutic uses as complement pathway modulators for the treatment of ocular diseases. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了一种化合物(I)的方法，用于制造该发明的化合物，并将其用作眼部疾病治疗的补体途径调节剂。本发明还提供了一种药理活性剂的组合和制药组合物。
• [EN] COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS<br/>[FR] COMPOSES ET COMPOSITIONS UTILISES COMME INHIBITEURS DE LA CATHEPSINE S
  申请人：NOVARTIS AG

  公开号：WO2006018284A1

  公开（公告）日：2006-02-23

  The present invention relates to the use of a 2-cyanopyrimidine compound of the formula (I), wherein R1, R2, R3 and X are as defined in the specification and in the claims, in free form or in salt form, and , where possible, in tautomeric form, as an inhibitor of the activity of cathepsin S.

  本发明涉及使用式(I)的2-氰基嘧啶化合物，其中R1、R2、R3和X如规范和权利要求中定义的那样，以自由形式或盐形式，并在可能的情况下以互变异构形式，作为猫hepsin S活性的抑制剂。
• COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS
  申请人：Hart Terance William

  公开号：US20090048230A1

  公开（公告）日：2009-02-19

  The present invention relates to the use of a 2-cyanopyrimidine compound of the formula wherein R 1 , R 2 , R 3 and X are as defined in the specification and in the claims, in free form or in salt form, and, where possible, in tautomeric form, as an inhibitor of the activity of cathepsin S.

  本发明涉及使用式中R1、R2、R3和X如规范和权利要求中定义的2-氰基嘧啶化合物的自由形式或盐形式及在可能的情况下互变异构体形式，作为猫hepsin S活性的抑制剂。
• PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS
  申请人：NOVARTIS AG

  公开号：US20150190457A1

  公开（公告）日：2015-07-09

  The present invention provides a compound of formula (I) a method for manufacturing the compounds of the invention, and its therapeutic uses as complement pathway modulators for the treatment of ocular diseases. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供一种式（I）的化合物，一种制造本发明化合物的方法，以及其作为补体途径调节剂治疗眼部疾病的治疗用途。本发明还提供了一种药理活性剂的组合和制药组合物。
• Compounds and compositions useful as cathepsin S inhibitors
  申请人：Novartis AG

  公开号：US07704996B2

  公开（公告）日：2010-04-27

  The present invention relates to the use of a 2-cyanopyrimidine compound of the formula wherein R1, R2, R3 and X are as defined in the specification and in the claims, in free form or in salt form, and, where possible, in tautomeric form, as an inhibitor of the activity of cathepsin S.

  本发明涉及使用式中R1、R2、R3和X如说明书和权利要求中所定义的2-氰基嘧啶化合物，以自由形式或盐形式，并在可能的情况下以互变异构体形式，作为猫蛋白S活性的抑制剂。